References
- Arrieta A, Page TF, Veledar E, et al. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One 2017;12:e0169761
- Jena AB, Blumenthal DM, Stevens W, et al. Value of improved lipid control in patients at high risk for adverse cardiac events. Am J Manag Care 2016;22:e199
- Gandra SR, Villa G, Fonarow GC, et al. Cost‐effectiveness of LDL‐C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol 2016;39:313-20
- Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. J Am Med Assoc 2016;316:743-53
- Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ 2017:1-10
- Institute for Clinical and Economic Review. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks. New England: Institute for Clinical and Economic Review; 2015
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. J Am Med Assoc 2016;316:1093-103
- Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003;6:9-17
- Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. New England: Oxford University Press; 2015
- Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008;372:2152-61
- Campbell JD, McQueen RB, Briggs A. The “e” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc 2014;11:S105-S111
- Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? J Asthma 2017;54:17-23
- Faria R, Hernandez Alava M, Manca A, et al. NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness for technology appraisal: methods for comparative individual patient data. Sheffield: NICE Decision Support Unit; 2015
- Kozak LJ, DeFrances CJ, Hall MJ. National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital and health statistics Series 13, Data from the National Health Survey. Atlanta, GA: National Center for Health Statistics; 2006:1-209
- Deedwania P, Stone PH, Merz CNB, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease. Circulation 2007;115:700-7
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-1722